miRNA-Regulated Gene Vector for HSC-Safe Transgene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hematopoietic gene therapy strategies face challenges in achieving stable integration of corrective DNA into the genome of hematopoietic stem cells without affecting cell function, and require regulated transgene expression to avoid toxicity and apoptosis, particularly in stem cells.
Innovation Solution
The use of gene vectors with miRNA sequences operably linked to nucleotide sequences that prevent or reduce transgene expression in hematopoietic stem cells and progenitor cells but allow expression in differentiated cells, utilizing miRNAs such as mir-130a, mir-126, and mir-223 to achieve specific expression profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transgene expression is maintained in hematopoietic stem cells to ensure long-term gene therapy efficacy, then therapeutic benefit is improved, but transgene toxicity and apoptosis increase
Solution Approach 1:
The patent applies local quality by creating spatially differentiated transgene expression: the transgene is expressed in differentiated hematopoietic cells (where it provides therapeutic benefit) but suppressed in hematopoietic stem cells (where it causes toxicity). This is achieved through cell-type-specific regulatory elements that control gene expression based on cellular differentiation state, allowing the same transgene to have different expression levels in different cell populations within the hematopoietic system.
2Duration of action of stationary object
If stable integration of corrective DNA is achieved in hematopoietic stem cells, then long-term gene correction is improved, but disruption of HSC function and apoptosis increase
Solution Approach 1:
The patent applies preliminary action by pre-establishing safe integration sites in the genome of hematopoietic stem cells before introducing the transgene. Using site-specific recombination systems, the corrective DNA is integrated into predetermined genomic locations that are known to be safe (non-disruptive to essential HSC genes). This preliminary preparation of integration sites ensures that long-term gene correction can be achieved without compromising HSC function or causing apoptosis.
3Productivity
If transgene expression is elevated to ensure therapeutic efficacy in differentiated cells, then disease correction is improved, but toxicity in stem cell progenitors increases
Solution Approach 1:
The patent applies dynamics by implementing temporal and conditional control of transgene expression. The transgene expression is dynamically regulated to be low or absent in early stem cells and progenitors, then progressively increased as cells differentiate into mature hematopoietic cells. This dynamic regulation is achieved through differentiation-responsive promoters and regulatory elements that respond to cellular maturation signals, ensuring therapeutic efficacy is achieved at the appropriate developmental stage without toxic effects on progenitor cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach ensures safe and effective gene therapy by preventing transgene toxicity in stem cells while maintaining therapeutic efficacy in differentiated progeny, enhancing the safety and efficacy of gene therapy protocols.
Implementation Method 1
at least one miRNA sequence target operably linked to a nucleotide sequence which prevents or reduces expression of the nucleotide sequence in a hematopoietic stem cell or a hematopoietic progenitor cell
Data Source
AI summary
A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.